Advances of liquid biopsy in the diagnosis and treatment of tumor

doi:10.3760/cma.j.issn.1673422X.2018.02.011

Abstract

Abstract: Liquid biopsy mainly focuses on tumor diagnosis, metastasis monitoring, individualized treatment monitoring, curative effect evaluation and prognostic judgment. The main targets include circulating tumor cells, circulating tumor DNA and exosomes. At present, the liquid biopsy target has been used in the clinical monitoring of some tumors, and has good clinical results, but there are still many challenges.

Key words: Neoplasm circulating cells, DNA, neoplasm, Tumor markers, biological, Liquid biopsy, Exosome　　

ZOU Jiang, GUO Xiao-Lan. Advances of liquid biopsy in the diagnosis and treatment of tumor[J]. Journal of International Oncology, 2018, 45(2): 107-111.

References

［1］ AlixPanabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA［J］. Annu Rev Med, 2012, 63: 199215. DOI: 10.1146/annurevmed062310094219. ［2］郭玮, 孙云帆, 潘柏申, 等. 循环肿瘤细胞检测及临床应用价值［J］. 中华临床实验室管理电子杂志, 2014, 2(3): 179184. DOI: 10.3877/cma.j.issn.20955820.03.011. ［3］ AlixPanabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy［J］. Cancer Discov, 2016, 6(5): 479491. DOI: 10.1158/21598290.CD151483. ［4］ Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of circulating tumor cells in cancer［J］. Mol Oncol, 2016, 10(3): 408417. DOI: 10.1016/j.molonc.2016.01.010. ［5］ Wu T, Cheng B, Fu L. Clinical applications of circulating tumor cells in pharmacotherapy: challenges and perspectives［J］. Mol Pharmacol, 2017, 92(3): 232239. DOI: 10.1124/mol.116.108142. ［6］ Yu Y, Chen Z, Dong J, et al. Folate receptorpositive circulating tumor cells as a novel diagnostic biomarker in nonsmall cell lung cancer［J］. Transl Oncol, 2013, 6(6): 697702. ［7］ Hegemann M, Stenzl A, Bedke J, et al. Liquid biopsy: ready to guide therapy in advanced prostate cancer?［J］. BJU Int, 2016, 118(6): 855863. DOI: 10.1111/bju.13586. ［8］ Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data［J］. Lancet Oncol, 2014, 15(4): 406414. DOI: 10.1016/S14702045(14)700695. ［9］ Janni WJ, Rack B, Terstappen LW, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer［J］. Clin Cancer Res, 2016, 22(10): 25832593. DOI: 10.1158/10780432.CCR151603. ［10］ Antonarakis ES, Lu C, Wang H, et al. ARV7 and resistance to enzalutamide and abiraterone in prostate cancer［J］. N Engl J Med, 2014, 371(11): 10281038. DOI: 10.1056/NEJMoa1315815. ［11］ Messaritakis I, Politaki E, Plataki M, et al. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib［J］. Lung Cancer, 2017, 104: 1623. DOI: 10.1016/j.lungcan.2016.12.008. ［12］ Huang MY, Tsai HL, Huang JJ, et al. Clinical implications and future perspectives of circulating tumor cells and biomarkers in clinical outcomes of colorectal cancer［J］. Transl Oncol, 2016, 9(4): 340347. DOI: 10.1016/j.tranon.2016.06.006. ［13］ Trapp EK, Majunke L, Zill B, et al. LKB1 prooncogenic activity triggers cell survival in circulating tumor cells［J］. Mol Oncol, 2017, 11(11): 15081526. DOI: 10.1002/18780261.12111. ［14］ Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individuallevel surrogate for survival in metastatic castrationresistant prostate cancer［J］. J Clin Oncol, 2015, 33(12): 13481355. DOI: 10.1200/JCO.2014.55.3487. ［15］ Li Y, Gong J, Zhang Q, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer［J］. Br J Cancer, 2016, 114(2): 138145. DOI: 10.1038/bjc.2015.417. ［16］ Lu CY, Tsai HL, Uen YH, et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage Ⅲ colon cancer［J］. Br J Cancer, 2013, 108(4): 791797. DOI: 10.1038/bjc.2012.595. ［17］ Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis［J］. Cell, 2014, 158(5): 11101122. DOI: 10.1016/j.cell.2014.07.013. ［18］ Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drugresistance［J］. Oncotarget, 2015, 6(13): 1069710711. DOI: 10.18632/oncotarget.4037. ［19］ Fiorelli A, Accardo M, Carelli E, et al. Circulating tumor cells in diagnosing lung cancer: clinical and morphologic analysis［J］. Ann Thorac Surg, 2015, 99(6): 18991905. DOI: 10.1016/j.athoracsur.2014.11.049. ［20］ Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA［J］. J Clin Oncol, 2014, 32(6): 579586. DOI: 10.1200/JCO.2012.45.2011. ［21］ Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer［J］. Clin Chem, 2015, 61(1): 112123. DOI: 10.1373/clinchem.2014.222679. ［22］ Zhang W, Xia W, Lv Z, et al. Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes?［J］. Cell Physiol Biochem, 2017, 41(2): 755768. DOI: 10.1159/000458736. ［23］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI: 10.1126/scitranslmed.3007094. ［24］ Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer［J］. N Engl J Med, 2013, 368(13): 11991209. DOI: 10.1056/NEJMoa1213261. ［25］ Romero D. Breast cancer: tracking ctDNA to evaluate relapse risk［J］. Nat Rev Clin Oncol, 2015, 12(11): 624. DOI: 10.1038/nrclinonc.2015.159. ［26］ Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to antiEGFR therapy in colorectal cancer［J］. Nature, 2012, 486(7404): 532536. DOI: 10.1038/nature11156. ［27］ Reinert T, Schler LV, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery［J］. Gut, 2016, 65(4): 625634. DOI: 10.1136/gutjnl2014308859. ［28］ Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics［J］. Nat Med, 2008, 14(9): 985990. DOI: 10.1038/nm.1789. ［29］ Calapre L, Warburton L, Millward M, et al. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma［J］. Cancer Lett, 2017, 404: 6269. DOI: 10.1016/j.canlet.2017.06.030. ［30］ Murtaza M, Dawson SJ, Tsui DW, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA［J］. Nature, 2013, 497(7447): 108112. DOI: 10.1038/nature12065. ［31］ Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFRmutant lung cancer using quantitative nextgeneration genotyping of cellfree plasma DNA［J］. Clin Cancer Res, 2014, 20(6): 16981705. DOI: 10.1158/10780432.CCR132482. ［32］ Xu B, Krie A, De P, et al. Utilizing tumor and plasma liquid biopsy in treatment decision making for an estrogen receptorpositive advanced breast cancer patient［J］. Cureus, 2017, 9(6): e1408. DOI: 10.7759/cureus.1408. ［33］ Tan CR, Zhou L, ElDeiry WS. Circulating tumor cells versus circulating tumor DNA in colorectal cancer: pros and cons［J］. Curr Colorectal Cancer Rep, 2016, 12(3): 151161. DOI: 10.1007/s118880160320y. ［34］ Kuderer NM, Burton KA, Blau S, et al. Comparison of 2 commercially available nextgeneration sequencing platforms in oncology［J］. JAMA Oncol, 2017, 3(7): 996998. DOI: 10.1001/jamaoncol.2016.4983. ［35］ Chae YK, Davis AA, Carneiro BA, et al. Concordance between genomic alterations assessed by nextgeneration sequencing in tumor tissue or circulating cellfree DNA［J］. Oncotarget, 2016, 7(40): 6536465373. DOI: 10.18632/oncotarget.11692. ［36］ Fais S, O′Driscoll L, Borras FE, et al. Evidencebased clinical use of nanoscale extracellular vesicles in nanomedicine［J］. ACS Nano, 2016, 10(4): 38863899. DOI: 10.1021/acsnano.5b08015. ［37］ Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes［J］. Curr Opin Cell Biol, 2014, 29: 116125. DOI: 10.1016/j.ceb.2014.05.004. ［38］ Ludwig AK, Giebel B. Exosomes: small vesicles participating in intercellular communication［J］. Int J Biochem Cell Biol, 2012, 44(1): 1115. DOI: 10.1016/j.biocel.2011.10.005. ［39］ Colombo E, Borgiani B, Verderio C, et al. Microvesicles: novel biomarkers for neurological disorders［J］. Front Physiol, 2012, 3: 63. DOI: 10.3389/fphys.2012.00063. ［40］ GamezValero A, LozanoRamos SI, Bancu I, et al. Urinary extracellular vesicles as source of biomarkers in kidney diseases［J］. Front Immunol, 2015, 6: 6. DOI: 10.3389/fimmu.2015.00006. ［41］ Khan S, Jutzy JM, Valenzuela MM, et al. Plasmaderived exosomal survivin, a plausible biomarker for early detection of prostate cancer［J］. PLoS One, 2012, 7(10): e46737. DOI: 10.1371/journal.pone.0046737. ［42］ Melo SA, Luecke LB, Kahlert C, et al. Glypican1 identifies cancer exosomes and detects early pancreatic cancer［J］. Nature, 2015, 523(7559): 177182. DOI: 10.1038/nature14581. ［43］ Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin1 in plasma of melanoma patients［J］. PLoS One, 2009, 4(4): e5219. DOI: 10.1371/journal.pone.0005219. ［44］ Szajnik M, Derbis M, Lach M, et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy［J］. Gynecol Obstet (Sunnyvale), 2013, Suppl 4: 3. DOI: 10.4172/21610932.S4003. ［45］ Ogorevc E, KraljIglic V, Veranic P. The role of extracellular vesicles in phenotypic cancer transformation［J］. Radiol Oncol, 2013, 47(3): 197205. DOI: 10.2478/raon20130037. ［46］ Campanella C, Rappa F, Sciumè C, et al. Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery［J］. Cancer, 2015, 121(18): 32303239. DOI: 10.1002/cncr.29499.

[1]	Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors [J]. Journal of International Oncology, 2021, 48(6): 358-361.
[2]	Tian Linghan, Zhu Ling, Liu Xin, Ye Jingwen, He Jiahui, Wang Xicai. Level of peripheral blood circulating tumor cells in lung cancer patients detected by CI-101 and its clinical significance [J]. Journal of International Oncology, 2020, 47(4): 199-204.
[3]	Ding Yu, Qiao Guibin. Research progress of liquid biopsy in early diagnosis of lung cancer [J]. Journal of International Oncology, 2019, 46(9): 548-552.
[4]	Zhang Fangyong, Wu Fan. Research progress on exosomederived noncoding RNAs in liquid biopsy of hepatocelluar carcinoma [J]. Journal of International Oncology, 2019, 46(6): 378-381.
[5]	Chen Luojun, Li Na, Tian Jingyuan, Song Qibin, Yu Jinming. Progress of circulating tumor cells in clinical application [J]. Journal of International Oncology, 2018, 45(8): 552-555.
[6]	Li Zhijian, He De. Research progress on liquid biopsy in pancreatic cancer [J]. Journal of International Oncology, 2018, 45(3): 180-182.
[7]	TANG Hui-Yun, MO Xiao-Yu, BAI Li-Ping, ZHENG Ai. Application of liquid biopsies in diagnosis and treatment of epithelial ovarian cancer [J]. Journal of International Oncology, 2018, 45(2): 122-125.
[8]	Yu Huajie*, Han Lu, Ou Yang, Li Sheng, Gao Dehai. Application of fluorescence in the identification of circulating tumor cells [J]. Journal of International Oncology, 2018, 45(1): 35-.
[9]	Ni-Ting, WANG Yu-Dong. Dissemination, detection and clinical use of circulating tumor cell [J]. Journal of International Oncology, 2015, 42(11): 841-844.
[10]	Gao Yang, Yuan Zhou. Research progress of nanotechnology in circulating tumor cell [J]. Journal of International Oncology, 2015, 42(1): 46-48.
[11]	WANG Huan-Sheng, LI Pang, LI Sheng. Establishment of circulating tumor cell linesWang [J]. Journal of International Oncology, 2014, 41(11): 805-807.
[12]	XIA Fan, ZHAO Teng, WANG Yan. Detection technique of circulating tumour cells in lung cancer [J]. Journal of International Oncology, 2012, 39(7): 523-525.